# Proof Of Concept : Immunogenicity and Safety of hepB Injection in the Dermis Using VAX-ID

> **NCT02186977** · PHASE1 · COMPLETED · sponsor: **Novosanis NV** · enrollment: 48 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DEVICE:** VAX-ID
- **DRUG:** 1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)
- **DRUG:** 0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD)

## Key facts

- **NCT ID:** NCT02186977
- **Lead sponsor:** Novosanis NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02186977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02186977, "Proof Of Concept : Immunogenicity and Safety of hepB Injection in the Dermis Using VAX-ID". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02186977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*